Informations générales (source: ClinicalTrials.gov)
Contribution of Multimodal Imaging (MRI, PET, MEG) in Pre-surgical Evaluation of Drug-resistant Focal Epilepsy (EPIMAGE)
Observational
Hospices Civils de Lyon (Voir sur ClinicalTrials)
octobre 2012
mai 2016
29 juin 2024
Epilepsy is the most common chronic neurological disorder in the world, affecting more
than 50 million people worldwide. Approximately 35% of patients with epilepsy are
refractory to all available antiepileptic drugs. Drug-resistant epilepsies are often
partial or focal. Patients with drug-resistant focal epilepsy suffer from an increased
risk of death, primarily due to seizure-related fatalities, in comparison with the
general population. The only therapeutic option for this form of epilepsy is the surgical
removal of the region of the brain responsible for seizures, called the epileptogenic
zone (EZ). This requires the precise localization of the EZ based on a comprehensive
pre-surgical evaluation of patients.
Today the gold standard for localizing the EZ and validating a non-invasive technique for
localization of the EZ remains intracerebral stereo-EEG (stereo-electroencephalography or
SEEG) recordings of spontaneous seizures. The implementation strategy of the
intracerebral depth electrodes is guided by clinical and neuroimaging data, including
anatomical Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) with FDG
(fluoro-Deoxy-Glucose) and MagnetoEncephaloGraphy (MEG). Although the contribution of
each technique in the pre-surgical localization of the EZ has already been shown, no
wide-scale study has examined the cumulative contribution of these three techniques.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Hospices Civils de Lyon - Lyon - France | Julien JUNG, Dr | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Patient with drug-resistant focal epilepsy
- Candidates for pre-surgical evaluation including FDG PET, MRI, MEG and SEEG
recordings.
- Age 18-65 years
- EEG-confirmed focal epilepsy for >2 years
- Signed informed consent form.
- Patient with drug-resistant focal epilepsy
- Candidates for pre-surgical evaluation including FDG PET, MRI, MEG and SEEG
recordings.
- Age 18-65 years
- EEG-confirmed focal epilepsy for >2 years
- Signed informed consent form.
- Age <18 years and >65 years
- Contraindication to the MRI
- Pregnant woman
- Head size incompatible with MEG recordings
- Adult subject to legal protection measure.